Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy

Completed · Phase 3 · Has a placebo group

Conditions studied: Peanut Allergy

In brief

The PEPITES study evaluates the efficacy and safety of Viaskin Peanut 250 µg peanut protein to induce desensitization to peanut in peanut-allergic children 4 through 11 years of age after a 12-month treatment by epicutaneous immunotherapy (EPIT).

Key facts

Study ID
NCT02636699
Run by
DBV Technologies
People needed
500
Starts
2015-12-01
Expected to finish
2017-08-18
Last updated by the study team
2025-06-18

Who can join

Age: 4 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.